| Bioactivity | Bocidelpar is a modulator of peroxisome proliferator-activated receptor delta (PPAR-δ). Bocidelpar improves mitochondrial biogenesis and function in Duchenne Muscular Dystrophy (DMD) muscle cells (extracted from patent WO2017062468A1, compound 2b)[1]. | ||||||||||||
| Target | PPAR-δ | ||||||||||||
| Name | Bocidelpar | ||||||||||||
| CAS | 2095128-20-2 | ||||||||||||
| Formula | C25H27F3N2O3 | ||||||||||||
| Molar Mass | 460.49 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Michael Downes, et al. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof. Patent WO2017062468A1. |
Bocidelpar
CAS: 2095128-20-2 F: C25H27F3N2O3 W: 460.49
Bocidelpar is a modulator of peroxisome proliferator-activated receptor delta (PPAR-δ). Bocidelpar improves mitochondri
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.